

=> d his

(FILE 'HOME' ENTERED AT 11:57:38 ON 03 OCT 2002)

FILE 'REGISTRY' ENTERED AT 11:57:44 ON 03 OCT 2002

L1 SCREEN 2016 OR 2026 OR 2039 OR 2040 OR 2045
 L2 STRUCTURE UPLOADED
 L3 QUE L2 NOT L1
 L4 0 S L3 SSS SAM
 L5 102 S L3 SSS FUL

FILE 'CAPLUS' ENTERED AT 12:00:02 ON 03 OCT 2002

L6 3 S L5

FILE 'CAOLD' ENTERED AT 12:00:45 ON 03 OCT 2002

=> s 15

L7 0 L5

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.38

155.57

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY



SESSION

CA SUBSCRIBER PRICE

0.00

-1.86

STN INTERNATIONAL LOGOFF AT 12:00:56 ON 03 OCT 2002



chain nodes :

13 14

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12

chain bonds :

4-13 8-13

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

exact/norm bonds :

4-13 8-13

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

isolated ring systems :

containing 1 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:CLASS 14:Atom 15:CLASS

Generic attributes :

14:

Saturation : Unsaturated

Number of Carbon Atoms : less than 7

Type of Ring System : Monocyclic

Element Count :

Node 14: Limited

C,C3

O,O1

N,N1

S,S0

101723, 113
~~101721, 695~~

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045

L1 SCREEN CREATED

=>

Uploading C:\STNEXP4\QUERIES\10171895.str

L2 STRUCTURE UPLOADED

=> que L2 NOT L1


L3 QUE L2 NOT L1

=> d 13

L3 HAS NO ANSWERS

L1 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045

L2 STR



Structure attributes must be viewed using STN Express query preparation.

L3 QUE L2 NOT L1

=> s 13 sss sam

SAMPLE SEARCH INITIATED 11:58:08 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1562 TO ITERATE

64.0% PROCESSED 1000 ITERATIONS

0 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 28870 TO 33610
PROJECTED ANSWERS: 0 TO 0

L4 0 SEA SSS SAM L2 NOT L1

=> s l3 sss ful
FULL SEARCH INITIATED 11:59:50 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 31818 TO ITERATE

100.0% PROCESSED 31818 ITERATIONS 102 ANSWERS
SEARCH TIME: 00.00.05

L5 102 SEA SSS FUL L2 NOT L1


=> s l5

L6 3 L5

=> d l6 1-3 bib,ab,hitstr

L6 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2002 ACS
AN 2002:449662 CAPLUS
DN 137:33310
TI Preparation of anilinopyrimidines as IKK inhibitors
IN Kois, Adam; MacFarlane, Karen J.; Satoh, Yoshitaka; Bhagwat, Shripad S.; Parnes, Jason S.; Palanki, Moorthy S. S.; Erdman, Paul E.
PA Signal Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 194 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002046171	A2	20020613	WO 2001-US46403	20011205
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002020195	A5	20020618	AU 2019-201950000220011205	
PRAI	US 2000-251816P	P	20001206	← 10/004,642 (not assigned).	
	WO 2001-US46403	W	20011205		
OS	MARPAT 137:33310				
AB	The title compds. [I; R1 = (un)substituted (hetero)aryl; R2 = H; R3 = H, alkyl; R4 = halo, OH, alkyl, alkoxy; R5, R6 = R8, (CH2)aCOR9, (CH2)aCO2R9, etc.; or NR5R6 = (un)substituted heterocycle; R8, R9 = H, alkyl, aryl, etc.; a = 0-4] having activity as inhibitors of IKK, particularly IKK-2, were prepd. E.g., a multi-step synthesis of I [R1 = 4-ClC6H4; R2-R6 = H] having an IC50 of .ltoreq. 1 .mu.M in the IKK-2 enzyme assay, was given. Such compds. I have utility in the treatment of a wide range of conditions that are responsive to IKK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compns. contg. one or more compds. of the above compds.				
IT	434945-29-6P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of anilinopyrimidines as IKK inhibitors)				
RN	434945-29-6 CAPLUS				
CN	Piperazine, 1-acetyl-4-[4-[4-(3-phenyl-5-isoxazolyl)-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)				



10/728,113
10/728,113

L6 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2002 ACS
AN 2002:449661 CAPLUS
DN 137:33309
TI Preparation of anilinopyrimidines as JNK pathway inhibitors
IN Kois, Adam; MacFarlane, Karen J.; Satoh, Yoshitaka; Bhagwat, Shripad S.;
Parnes, Jason S.; Palanki, Moorthy S. S.; Erdman, Paul E.
PA Signal Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 199 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002046170	A2	20020613	WO 2001-US46402	20011205
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002027214	A5	20020618	AU 2002-27214	20011205
PRAI	US 2000-251904P	P	20001206	← 101084,645 (not assigned).	
	WO 2001-US46402	W	20011205		
OS	MARPAT 137:33309				
AB	The title compds. [I; R1 = (un)substituted (hetero)aryl; R2 = H; R3 = H, alkyl; R4 = halo, OH, alkyl, alkoxy; R5, R6 = R8, (CH2)aCOR9, (CH2)aCO2R9, etc.; or NR5R6 = (un)substituted heterocycle; R8, R9 = H, alkyl, aryl, etc.; a = 0-4] having activity as inhibitors of the JNK pathway, were prepd. E.g., a multi-step synthesis of I [R1 = 4-ClC6H4; R2-R6 = H] having an IC50 of .ltoreq. 10 .mu.M in the JNK2 assay, was given. Such compds. I have utility in the treatment of a wide range of conditions that are responsive to inhibition of the JNK pathway. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compns. contg. one or more compds. of the above compds.				
IT	434945-29-6P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of anilinopyrimidines as JNK pathway inhibitors)				
RN	434945-29-6 CAPLUS				
CN	Piperazine, 1-acetyl-4-[4-[[4-(3-phenyl-5-isoxazolyl)-2- pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)				



10/928,113
~~10/171,835~~

L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2002 ACS
 AN 2001:137207 CAPLUS
 DN 134:178569
 TI Preparation of as isoxazolylypyrimidines and related compounds as
 inhibitors of c-JUN N-terminal kinases and other protein kinases.
 IN Green, Jeremy; Bemis, Guy; Grillot, Anne-Laure; Ledebuer, Mark; Salituro,
 Francis; Harrington, Edmund; Gao, Huai; Baker, Christopher; Cao, Jingrong;
 Hale, Michael
 PA Vertex Pharmaceuticals Incorporated, USA
 SO PCT Int. Appl., 96 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001012621	A1	20010222	WO 2000-US22445	20000811
	W:				
					AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
	EP 1218369	A1	20020703	EP 2000-957485	20000811
	R:				AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL
	NO 2002000713	A	20020412	NO 2002-713	20020212
PRAI	US 1999-148795P	P	19990812		
	US 1999-166922P	P	19991122		
	US 2000-211517P	P	20000614		
	WO 2000-US22445	W	20000811		
OS	MARPAT 134:178569				
AB	Title compds. [I; XYZ = NOCR2, ON:CR2, N:NNR3, OC(R2):CR2, NN(R3)CR2; R1 = H, CONH2, TnR, TnAr2; R = (substituted) alipharyl; n = 0, 1; T = CO, CO2, CONH, SO2, SO2NH, COCH2, CH2; R2 = H, R, CH2OR, CH2OH, CHO, CH2SR, CH2SO2R, CH2NH2, CH2CN, (substituted) aryl, arylmethyl, heterocyclyl, heterocyclylmethyl, etc.; R3 = H, R, COR, CO2R, SO2R; G = R, Ar1; Ar1 = (substituted) (fused) aryl, aralkyl, heterocyclyl; Q = Q1, Q2; A = N, CR3; U = CR3, O, S, NR3; Ar2 = (substituted) (fused) aryl, heterocyclyl], were prepd. Thus, 4-(5-methyl-3-phenylisoxazole-4-yl)pyrimidin-2-ylamine (prepn. given) was refluxed with PhBr, tris(dibenzylideneacetone)dipalladi- um, BINAP, and NaOCMe3 were refluxed together for 16 h to give 36% 4-(5-methyl-3-phenylisoxazole-4-yl)pyrimidin-2-ylphenylamine. Several I inhibited KNK3 at <0.1 .mu.M.				
IT	326817-95-2P RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of as isoxazolylypyrimidines and related compds. as inhibitors of c-JUN N-terminal kinases and other protein kinases)				
RN	326817-95-2 CAPLUS				
CN	2-Pyrimidinamine, 4-(5-methyl-3-phenyl-4-isoxazolylyl)-N-phenyl- (9CI) (CA INDEX NAME)				




IT 326818-22-8 326818-24-0 326818-26-2
 326818-27-3 326818-29-5 326818-31-9
 326818-32-0 326818-34-2 326818-37-5
 326818-38-6 326818-39-7 326818-40-0
 326818-41-1 326818-42-2 326818-43-3
 326818-44-4 326818-45-5 326818-46-6
 326818-47-7 326818-48-8 326818-50-2
 326818-51-3 326818-53-5 326818-55-7
 326818-56-8 326818-59-1 326818-61-5
 326818-63-7 326818-64-8 326818-65-9
 326818-66-0 326818-67-1 326818-68-2
 326818-69-3 326818-71-7 326818-72-8
 326818-75-1 326818-76-2 326818-77-3
 326818-78-4 326818-79-5 326818-80-8
 326818-81-9 326818-82-0 326818-83-1
 326818-84-2 326818-85-3 326818-86-4
 326818-88-6 326818-89-7 326818-90-0
 326818-91-1 326818-92-2 326818-93-3
 326818-94-4 326818-95-5 326818-96-6
 326818-97-7 326819-02-7 326819-03-8
 326819-04-9 326819-05-0 326819-06-1
 326819-07-2 326819-08-3 326819-09-4
 326819-10-7 326819-11-8 326819-12-9
 326819-13-0 326819-14-1 326819-15-2
 326819-17-4 326819-18-5 326819-19-6
 326819-20-9 326819-22-1 326819-23-2
 326819-24-3 326819-25-4 326819-26-5
 326819-27-6 326819-28-7 326819-29-8
 326819-30-1 326819-31-2 326819-35-6
 326819-36-7 326819-37-8 326819-41-4
 326819-42-5 326819-43-6 326819-44-7
 326819-45-8 326819-46-9 326819-47-0
 326819-48-1 326819-50-5 326819-51-6
 326819-52-7

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(prepn. of as isoxazolylpyrimidines and related compds. as inhibitors of c-JUN N-terminal kinases and other protein kinases)


RN 326818-22-8 CAPLUS

CN 2-Pyrimidinamine, N-(3,4-dimethoxyphenyl)-4-(5-methyl-3-phenyl-4-isoxazolyl)- (9CI) (CA INDEX NAME)




RN 326818-24-0 CAPLUS

CN Benzamide, 3-methyl-4-[[4-(5-methyl-3-phenyl-4-isoxazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 326818-26-2 CAPLUS

CN Benzonitrile, 3-methyl-4-[[4-(5-methyl-3-phenyl-4-isoxazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 326818-27-3 CAPLUS

CN Benzonitrile, 3-[[4-(5-methyl-3-phenyl-4-isoxazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 326818-29-5 CAPLUS

CN 2-Pyrimidinamine, N-(3-fluoro-2-methylphenyl)-4-(5-methyl-3-phenyl-4-isoxazolyl)- (9CI) (CA INDEX NAME)




RN 326818-31-9 CAPLUS

CN 2-Pyrimidinamine, N-(4-fluoro-2-methylphenyl)-4-(5-methyl-3-phenyl-4-isoxazolyl)- (9CI) (CA INDEX NAME)




RN 326818-32-0 CAPLUS

CN 2-Pyrimidinamine, 4-(5-methyl-3-phenyl-4-isoxazolyl)-N-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 326818-34-2 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(4-fluorophenyl)-5-methyl-4-isoxazolyl]-N-phenyl-
(9CI) (CA INDEX NAME)




RN 326818-37-5 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(2,3-dimethoxyphenyl)-5-methyl-4-isoxazolyl]-N-phenyl-
(9CI) (CA INDEX NAME)




RN 326818-38-6 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(2,4-dimethoxyphenyl)-5-methyl-4-isoxazolyl]-N-phenyl-
(9CI) (CA INDEX NAME)




RN 326818-39-7 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(2-chlorophenyl)-5-methyl-4-isoxazolyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 326818-40-0 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(3,4-dichlorophenyl)-5-methyl-4-isoxazolyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 326818-41-1 CAPLUS

CN Benzonitrile, 2-fluoro-4-[[4-(5-methyl-3-phenyl-4-isoxazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 326818-42-2 CAPLUS

CN 2-Pyrimidinamine, N-(3-fluorophenyl)-4-(5-methyl-3-phenyl-4-isoxazolyl)-
(9CI) (CA INDEX NAME)




RN 326818-43-3 CAPLUS

CN Benzonitrile, 4-[[4-(5-methyl-3-phenyl-4-isoxazolyl)-2-pyrimidinyl]amino]-
(9CI) (CA INDEX NAME)




RN 326818-44-4 CAPLUS

CN Ethanone, 1-[4-[[4-(5-methyl-3-phenyl-4-isoxazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 326818-45-5 CAPLUS

CN 2-Pyrimidinamine, N-(3-ethenylphenyl)-4-(5-methyl-3-phenyl-4-isoxazolyl)-
(9CI) (CA INDEX NAME)




RN 326818-46-6 CAPLUS

CN 2-Pyrimidinamine, 4-(5-methyl-3-phenyl-4-isoxazolyl)-N-[3-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 326818-47-7 CAPLUS

CN Benzonitrile, 2-methyl-4-[[4-(5-methyl-3-phenyl-4-isoxazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 326818-48-8 CAPLUS

CN Ethanone, 1-[3-[[4-(5-methyl-3-phenyl-4-isoxazolyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 326818-50-2 CAPLUS

CN 2-Pyrimidinamine, N-(2-methoxyphenyl)-4-(5-methyl-3-phenyl-4-isoxazolyl)-
(9CI) (CA INDEX NAME)




RN 326818-51-3 CAPLUS

CN 2-Pyrimidinamine, N-(4-fluorophenyl)-4-(5-methyl-3-phenyl-4-isoxazolyl)-
(9CI) (CA INDEX NAME)




RN 326818-53-5 CAPLUS

CN 2-Pyrimidinamine, N-[1,1'-biphenyl]-4-yl-4-(5-methyl-3-phenyl-4-isoxazolyl)-
(9CI) (CA INDEX NAME)




RN 326818-55-7 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-(5-methyl-3-phenyl-4-isoxazolyl)- (9CI) (CA INDEX NAME)




RN 326818-56-8 CAPLUS

CN 2-Pyrimidinamine, 4-(5-methyl-3-phenyl-4-isoxazolyl)-N-[4-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 326818-59-1 CAPLUS

CN Benzonitrile, 4-methoxy-3-[[4-(5-methyl-3-phenyl-4-isoxazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 326818-61-5 CAPLUS

CN Benzonitrile, 4-fluoro-3-[[4-(5-methyl-3-phenyl-4-isoxazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 326818-63-7 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(2-fluorophenyl)-5-methyl-4-isoxazolyl]-N-phenyl-
(9CI) (CA INDEX NAME)




RN 326818-64-8 CAPLUS

CN 2-Pyrimidinamine, N-(2,4-difluorophenyl)-4-(5-methyl-3-phenyl-4-
isoxazolyl)- (9CI) (CA INDEX NAME)




RN 326818-65-9 CAPLUS

CN 2-Pyrimidinamine, N-(3-chloro-2-methylphenyl)-4-(5-methyl-3-phenyl-4-
isoxazolyl)- (9CI) (CA INDEX NAME)




RN 326818-66-0 CAPLUS

CN 2-Pyrimidinamine, N-(2-fluorophenyl)-4-(5-methyl-3-phenyl-4-isoxazolyl)-
(9CI) (CA INDEX NAME)




RN 326818-67-1 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(2,6-difluorophenyl)-5-methyl-4-isoxazolyl]-N-
phenyl- (9CI) (CA INDEX NAME)




RN 326818-68-2 CAPLUS

CN 2-Pyrimidinamine, N-(4-methoxy-2-methylphenyl)-4-(5-methyl-3-phenyl-4-
isoxazolyl)- (9CI) (CA INDEX NAME)




RN 326818-69-3 CAPLUS

CN 2-Pyrimidinamine, 4-(5-methyl-3-phenyl-4-isoxazolyl)-N-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 326818-71-7 CAPLUS

CN 2-Pyrimidinamine, 4-(5-methyl-3-phenyl-4-isoxazolyl)-N-(2-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 326818-72-8 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(3-fluorophenyl)-5-methyl-4-isoxazolyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 326818-75-1 CAPLUS

CN 2-Pyrimidinamine, N-(2-ethenylphenyl)-4-(5-methyl-3-phenyl-4-isoxazolyl)-
(9CI) (CA INDEX NAME)


RN 326818-76-2 CAPLUS

CN 2-Pyrimidinamine, N-(2-chloro-5-methoxyphenyl)-4-(5-methyl-3-phenyl-4-isoxazolyl)- (9CI) (CA INDEX NAME)




RN 326818-77-3 CAPLUS

CN 2-Pyrimidinamine, N-(4-methoxy-3-methylphenyl)-4-(5-methyl-3-phenyl-4-isoxazolyl)- (9CI) (CA INDEX NAME)




RN 326818-78-4 CAPLUS

CN 2-Pyrimidinamine, N-(2,5-dimethylphenyl)-4-(5-methyl-3-phenyl-4-isoxazolyl)- (9CI) (CA INDEX NAME)




RN 326818-79-5 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(2,5-difluorophenyl)-5-methyl-4-isoxazolyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 326818-80-8 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(2-chloro-6-fluorophenyl)-5-methyl-4-isoxazolyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 326818-81-9 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(2-bromophenyl)-5-methyl-4-isoxazolyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 326818-82-0 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(2,3-difluorophenyl)-5-methyl-4-isoxazolyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 326818-83-1 CAPLUS

CN 2-Pyrimidinamine, 4-(5-methyl-3-phenyl-4-isoxazolyl)-N-[2-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 326818-84-2 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-3-[3-(trifluoromethyl)phenyl]-4-isoxazolyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 326818-85-3 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(3,5-difluorophenyl)-5-methyl-4-isoxazolyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 326818-86-4 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(2,6-dichlorophenyl)-5-methyl-4-isoxazolyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 326818-88-6 CAPLUS

CN 2-Pyrimidinamine, 4-(3,5-dimethyl-4-isoxazolyl)-N-phenyl- (9CI) (CA INDEX NAME)




RN 326818-89-7 CAPLUS

CN 2-Pyrimidinamine, 4-(3-cyclopropyl-5-methyl-4-isoxazolyl)-N-phenyl- (9CI)
(CA INDEX NAME)




RN 326818-90-0 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(1,1-dimethylethyl)-5-methyl-4-isoxazolyl]-N-phenyl-
(9CI) (CA INDEX NAME)




RN 326818-91-1 CAPLUS

CN Ethanone, 1-[4-[[4-[3-(2,5-difluorophenyl)-5-methyl-4-isoxazolyl]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 326818-92-2 CAPLUS

CN Benzonitrile, 3-[[4-[3-(2,5-difluorophenyl)-5-methyl-4-isoxazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 326818-93-3 CAPLUS

CN Benzonitrile, 4-[[4-[3-(2,5-difluorophenyl)-5-methyl-4-isoxazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 326818-94-4 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(2,5-difluorophenyl)-5-methyl-4-isoxazolyl]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 326818-95-5 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(2,5-difluorophenyl)-5-methyl-4-isoxazolyl]-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 326818-96-6 CAPLUS

CN Benzonitrile, 5-[[4-[3-(2,5-difluorophenyl)-5-methyl-4-isoxazolyl]-2-pyrimidinyl]amino]-2-fluoro- (9CI) (CA INDEX NAME)




RN 326818-97-7 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(2,5-difluorophenyl)-5-methyl-4-isoxazolyl]-N-[4-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 326819-02-7 CAPLUS

CN 2-Pyrimidinamine, N-(3-methylphenyl)-4-(5-methyl-3-phenyl-4-isoxazolyl)-
(9CI) (CA INDEX NAME)




RN 326819-03-8 CAPLUS

CN 2-Pyrimidinamine, N-(4-methylphenyl)-4-(5-methyl-3-phenyl-4-isoxazolyl)-
(9CI) (CA INDEX NAME)




RN 326819-04-9 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-3-(2-methylphenyl)-4-isoxazolyl]-N-phenyl-
(9CI) (CA INDEX NAME)




RN 326819-05-0 CAPLUS

CN Benzonitrile, 2-fluoro-4-[[4-[5-methyl-3-(2-methylphenyl)-4-isoxazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 326819-06-1 CAPLUS

CN 2-Pyrimidinamine, N-(3-fluorophenyl)-4-[5-methyl-3-(2-methylphenyl)-4-isoxazolyl]- (9CI) (CA INDEX NAME)




RN 326819-07-2 CAPLUS

CN Benzonitrile, 4-[[4-[5-methyl-3-(2-methylphenyl)-4-isoxazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 326819-08-3 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-3-(2-methylphenyl)-4-isoxazolyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 326819-09-4 CAPLUS

CN Benzonitrile, 3-[[4-[5-methyl-3-(2-methylphenyl)-4-isoxazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 326819-10-7 CAPLUS

CN Benzonitrile, 2-fluoro-4-[[4-[5-methyl-3-[2-(trifluoromethyl)phenyl]-4-isoxazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 326819-11-8 CAPLUS

CN Benzonitrile, 3-[[4-[5-methyl-3-[2-(trifluoromethyl)phenyl]-4-isoxazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 326819-12-9 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-3-[2-(trifluoromethyl)phenyl]-4-isoxazolyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 326819-13-0 CAPLUS

CN Benzonitrile, 4-[[4-[3-(1,3-benzodioxol-5-yl)-5-methyl-4-isoxazolyl]-2-pyrimidinyl]amino]-2-fluoro- (9CI) (CA INDEX NAME)




RN 326819-14-1 CAPLUS

CN Benzonitrile, 3-[[4-[3-(1,3-benzodioxol-5-yl)-5-methyl-4-isoxazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 326819-15-2 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(1,3-benzodioxol-5-yl)-5-methyl-4-isoxazolyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 326819-17-4 CAPLUS

CN Benzonitrile, 2-fluoro-4-[[4-[5-methyl-3-[3-(phenylmethoxy)phenyl]-4-isoxazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 326819-18-5 CAPLUS

CN Benzonitrile, 3-[[4-[5-methyl-3-[3-(phenylmethoxy)phenyl]-4-isoxazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 326819-19-6 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-3-[3-(phenylmethoxy)phenyl]-4-isoxazolyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 326819-20-9 CAPLUS

CN Benzonitrile, 2-fluoro-4-[[4-[5-methyl-3-(3-nitrophenyl)-4-isoxazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 326819-22-1 CAPLUS

CN Benzonitrile, 3-[[4-[5-methyl-3-(3-nitrophenyl)-4-isoxazolyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 326819-23-2 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-3-(3-nitrophenyl)-4-isoxazolyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 326819-24-3 CAPLUS

CN Benzonitrile, 4-[[4-[3-(3-cyanophenyl)-5-methyl-4-isoxazolyl]-2-pyrimidinyl]amino]-2-fluoro- (9CI) (CA INDEX NAME)




RN 326819-25-4 CAPLUS

CN Benzonitrile, 3-[4-[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]-5-methyl-3-isoxazolyl]- (9CI) (CA INDEX NAME)




RN 326819-26-5 CAPLUS

CN Benzonitrile, 3-[4-[2-[(3-cyanophenyl)amino]-4-pyrimidinyl]-5-methyl-3-isoxazolyl]- (9CI) (CA INDEX NAME)




RN 326819-27-6 CAPLUS

CN Benzonitrile, 3-[5-methyl-4-[2-(phenylamino)-4-pyrimidinyl]-3-isoxazolyl]- (9CI) (CA INDEX NAME)




RN 326819-28-7 CAPLUS

CN Benzoic acid, 4-[[4-[5-methyl-3-(3-nitrophenyl)-4-isoxazolyl]-2-pyrimidinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 326819-29-8 CAPLUS

CN Benzoic acid, 3-[[4-[3-(3-cyanophenyl)-5-methyl-4-isoxazolyl]-2-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 326819-30-1 CAPLUS

CN Benzoic acid, 3-[[4-(5-methyl-3-phenyl-4-isoxazolyl)-2-pyrimidinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 326819-31-2 CAPLUS

CN 2-Pyrimidinamine, 4-(5-methyl-3-phenyl-4-isoxazolyl)-N-(4-nitrophenyl)-
(9CI) (CA INDEX NAME)




RN 326819-35-6 CAPLUS

CN 2-Pyrimidinamine, 4-(5-methyl-3-phenyl-4-isoxazolyl)-N-2-naphthalenyl-
(9CI) (CA INDEX NAME)



RN 326819-36-7 CAPLUS


CN 2-Pyrimidinamine, N-(6-methoxy-2-naphthalenyl)-4-(5-methyl-3-phenyl-4-isoxazolyl)-
(9CI) (CA INDEX NAME)



RN 326819-37-8 CAPLUS


CN 1H-Inden-1-one, 2,3-dihydro-5-[[4-(5-methyl-3-phenyl-4-isoxazolyl)-2-

pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 326819-41-4 CAPLUS

CN 2-Pyrimidinamine, 4-(5-methyl-3-phenyl-4-isoxazolyl)-N-1-naphthalenyl- (9CI) (CA INDEX NAME)




RN 326819-42-5 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(2,6-difluorophenyl)-5-methyl-4-isoxazolyl]-N-(6-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME).




RN 326819-43-6 CAPLUS

CN 2-Pyrimidinamine, N-(2-methyl-1-naphthalenyl)-4-(5-methyl-3-phenyl-4-isoxazolyl)- (9CI) (CA INDEX NAME)




RN 326819-44-7 CAPLUS

CN 2-Naphthalenecarboxylic acid, 6-[[4-(5-methyl-3-phenyl-4-isoxazolyl)-2-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 326819-45-8 CAPLUS

CN 2-Pyrimidinamine, N-(2-methoxy-1-naphthalenyl)-4-(5-methyl-3-phenyl-4-isoxazolyl)- (9CI) (CA INDEX NAME)




RN 326819-46-9 CAPLUS

CN 2-Pyrimidinamine, N-[2-(methoxymethyl)-1-naphthalenyl]-4-(5-methyl-3-phenyl-4-isoxazolyl)- (9CI) (CA INDEX NAME)




RN 326819-47-0 CAPLUS

CN 2-Pyrimidinamine, N-(6-methoxy-2-naphthalenyl)-4-[5-methyl-3-(2-methylphenyl)-4-isoxazolyl]- (9CI) (CA INDEX NAME)




RN 326819-48-1 CAPLUS

CN 6-Quinolinamine, 2-methyl-N-[4-[5-methyl-3-(2-methylphenyl)-4-isoxazolyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 326819-50-5 CAPLUS

CN 6-Quinolinamine, N-[4-[3-(1,3-benzodioxol-5-yl)-5-methyl-4-isoxazolyl]-2-pyrimidinyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 326819-51-6 CAPLUS

CN 6-Quinolinamine, 2-methyl-N-[4-[5-methyl-3-(3-nitrophenyl)-4-isoxazolyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 326819-52-7 CAPLUS

CN Benzonitrile, 3-[5-methyl-4-[2-[(2-methyl-6-quinolinyl)amino]-4-pyrimidinyl]-3-isoxazolyl]- (9CI) (CA INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT